ClinicalTrials.gg
CompletedNCT05859698Updated Jan 16, 2026Results posted

Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia

A Phase 4 interventional study of Valbenazine in Schizophrenia, Schizoaffective Disorder and Bipolar Disorder, sponsored by Neurocrine Biosciences. Completed at 18 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-16.

Sponsored by Neurocrine Biosciences · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
59
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Schizophrenia by Neurocrine Biosciences — 6 open to participants now, 6 under way, 4 of them phase 3. Schizophrenia · Neurocrine Biosciences.

Enrollment
13th of 16
59 · median 165
Started
2023
with 1 other
Phase 4
2 of 16
1 open now
Registered
10th of 16
by date

Among the 16 studies in Schizophrenia by Neurocrine Biosciences, this one is the 13th largest by enrollment, is one of 2 that started in 2023, is one of 2 in phase 4, and was the 10th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

6 of the 16 studies in Schizophrenia by Neurocrine Biosciences are open now, in 7 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Schizophrenia by Neurocrine Biosciences, or all of them as a file.
02

Study summary

This study will evaluate the effectiveness of valbenazine on patient- and clinician-reported outcomes assessing health-related quality of life, functioning, and treatment effect in participants with tardive dyskinesia (TD) who are receiving valbenazine for up to 24 weeks.

03

Conditions studied

  • Schizophrenia
  • Schizoaffective Disorder
  • Bipolar Disorder
  • Major Depressive Disorder
  • Tardive Dyskinesia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • At least 18 years of age
  • Have one of the following clinical diagnoses: schizophrenia or schizoaffective disorder, bipolar disorder, or major depressive disorder
  • Have a clinical diagnosis of neuroleptic-induced TD
  • Medication(s) for schizophrenia or schizoaffective disorder, bipolar disorder, or major depressive disorder and other protocol-allowed concurrent medications must be at a stable dose and expected to remain stable during the study
  • Participants must be outpatients and have a stable psychiatric status

Key Exclusion Criteria:

  • Have comorbid abnormal involuntary movement(s) (for example, Parkinsonism, akathisia) that is more prominent than TD
  • Have an active, unstable medical condition in the judgement of the investigator, or have any laboratory value outside the normal range that is considered by the investigator to be clinically significant at the screening visit
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    Valbenazine

    Valbenazine administered once daily for 24 weeks.

    Drug: Valbenazine

Interventions

  • Valbenazine capsules for oral administration

    Also known as: NBI-98854

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Tardive Dyskinesia Impact Scale (TDIS) Total Score at Week 24

    The TDIS assesses the impact of impairment and disability associated with dyskinesia. It defines impact of tardive dyskinesia (TD) in terms of 6 scales: Mouth/Throat Function (3 items), Dexterity (2 items), Mobility (2 items), Pain (1 item), Emotional (2 items), and Social (1 item). Each item measured the impact of dyskinetic movements in terms of difficulty or frequency over the last 7 days on a 5-point scale, with scores ranging from 0 to 4. Response options for the difficulty items ranged from not at all (0) to extremely (4); those for the frequency items ranged from never (0) to all of the time (4). The TDIS total score was the sum of the scores of TDIS Items 1 to 11. Total scores ranged from 0 to 44, with higher scores representing greater TD impact.

    Time frame: Baseline, Week 24

  2. Change From Baseline in the Sheehan Disability Scale (SDS) Items 1, 2, and 3 Score at Week 24

    The SDS included 3 self-rated items designed to measure how work, social life, and family life are impaired by current psychiatric symptoms. Each item includes an 11-point analog scale that uses visual-spatial, numeric, and verbal descriptive anchors to represent the degree of disruption from 0 (none at all) to 10 (extremely). Participants who had not worked for pay or attended school in the previous 7 days for reasons unrelated to TD did not respond to Item 1 and were therefore excluded from the analysis of that item.

    Time frame: Baseline, Week 24

  3. Change From Baseline in the Euro Quality of Life Visual Analogue Scale (EQ-VAS) Score at Week 24

    Participants rated their overall health on a 0 to 100 hash-marked, vertical EQ-VAS where 0 represents 'The worst health you can imagine' and 100 represents 'The best health you can imagine.' An increase from baseline indicates an increase in overall health.

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Patient Global Impression of Change (PGI-C) Score at Week 24

    Participants rated the change in their TD symptoms from the initiation of study treatment dosing by choosing one of 7 responses (1=very much improved, 2=much improved, 3=minimally improved, 4=not changed, 5=minimally worse, 6=much worse, and 7=very much worse). Number of participants with PGI-C score responses are reported.

    Time frame: Week 24

  2. Change From Baseline in the Clinical Global Impression of Severity - Tardive Dyskinesia (CGI-TD-S) Score at Week 24

    The CGI-TD-S is based on a 7-point scale (range; 1=normal, not at all ill to 7=among the most extremely ill patients), was used to rate the overall global severity of TD.

    Time frame: Baseline, Week 24

  3. Change From Baseline in the Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score at Week 24

    The AIMS dyskinesia total score was defined as the sum of the scores of AIMS items 1 through 7. The scores for each item ranged from 0 (no dyskinesia) to 4 (severe dyskinesia). If any of the seven items had a missing value, the total score for that participant/visit was set equal to missing. The AIMS dyskinesia total score can therefore range from 0 to 28, with higher scores indicating greater severity.

    Time frame: Baseline, Week 24

07

Results

Posted Jan 16, 2026

Participant flow

Participant flow — Overall Study
MilestoneValbenazine
Started59
Received at least 1 dose of valbenazine59
Completed51
Not completed8
Withdrew: Adverse event1
Withdrew: Death1
Withdrew: Physician decision1
Withdrew: Lost to follow-up2
Withdrew: Other than specified2
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryChange From Baseline in the Tardive Dyskinesia Impact Scale (TDIS) Total Score at Week 24

The TDIS assesses the impact of impairment and disability associated with dyskinesia. It defines impact of tardive dyskinesia (TD) in terms of 6 scales: Mouth/Throat Function (3 items), Dexterity (2 items), Mobility (2 items), Pain (1 item), Emotional (2 items), and Social (1 item). Each item measured the impact of dyskinetic movements in terms of difficulty or frequency over the last 7 days on a 5-point scale, with scores ranging from 0 to 4. Response options for the difficulty items ranged from not at all (0) to extremely (4); those for the frequency items ranged from never (0) to all of the time (4). The TDIS total score was the sum of the scores of TDIS Items 1 to 11. Total scores ranged from 0 to 44, with higher scores representing greater TD impact.

Time frame:
Baseline, Week 24
Reported as:
Mean · score on a scale
Change From Baseline in the Tardive Dyskinesia Impact Scale (TDIS) Total Score at Week 24
score on a scaleValbenazine
Change From Baseline in the Tardive Dyskinesia Impact Scale (TDIS) Total Score at Week 24-8.0 (-10.48 to -5.44)
PrimaryChange From Baseline in the Sheehan Disability Scale (SDS) Items 1, 2, and 3 Score at Week 24

The SDS included 3 self-rated items designed to measure how work, social life, and family life are impaired by current psychiatric symptoms. Each item includes an 11-point analog scale that uses visual-spatial, numeric, and verbal descriptive anchors to represent the degree of disruption from 0 (none at all) to 10 (extremely). Participants who had not worked for pay or attended school in the previous 7 days for reasons unrelated to TD did not respond to Item 1 and were therefore excluded from the analysis of that item.

Time frame:
Baseline, Week 24
Reported as:
Mean · score on a scale
Change From Baseline in the Sheehan Disability Scale (SDS) Items 1, 2, and 3 Score at Week 24
score on a scaleValbenazine
Item 1: Work/School Impairment-1.2 (-2.98 to 0.58)
Item 2: Social Life Impairment-2.3 (-3.23 to -1.43)
Item 3: Family Life/Home Responsibilities-1.6 (-2.54 to -0.57)
PrimaryChange From Baseline in the Euro Quality of Life Visual Analogue Scale (EQ-VAS) Score at Week 24

Participants rated their overall health on a 0 to 100 hash-marked, vertical EQ-VAS where 0 represents 'The worst health you can imagine' and 100 represents 'The best health you can imagine.' An increase from baseline indicates an increase in overall health.

Time frame:
Baseline, Week 24
Reported as:
Mean · score on a scale
Change From Baseline in the Euro Quality of Life Visual Analogue Scale (EQ-VAS) Score at Week 24
score on a scaleValbenazine
Change From Baseline in the Euro Quality of Life Visual Analogue Scale (EQ-VAS) Score at Week 2413.1 (7.70 to 18.48)
SecondaryPatient Global Impression of Change (PGI-C) Score at Week 24

Participants rated the change in their TD symptoms from the initiation of study treatment dosing by choosing one of 7 responses (1=very much improved, 2=much improved, 3=minimally improved, 4=not changed, 5=minimally worse, 6=much worse, and 7=very much worse). Number of participants with PGI-C score responses are reported.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Patient Global Impression of Change (PGI-C) Score at Week 24
ParticipantsValbenazine
1 = Very Much Improved13
2 = Much Improved19
3 = Minimally Improved10
4 = Not Changed2
5 = Minimal Worse1
6 = Much Worse0
7 = Very Much Worse0
SecondaryChange From Baseline in the Clinical Global Impression of Severity - Tardive Dyskinesia (CGI-TD-S) Score at Week 24

The CGI-TD-S is based on a 7-point scale (range; 1=normal, not at all ill to 7=among the most extremely ill patients), was used to rate the overall global severity of TD.

Time frame:
Baseline, Week 24
Reported as:
Mean · score on a scale
Change From Baseline in the Clinical Global Impression of Severity - Tardive Dyskinesia (CGI-TD-S) Score at Week 24
score on a scaleValbenazine
Change From Baseline in the Clinical Global Impression of Severity - Tardive Dyskinesia (CGI-TD-S) Score at Week 24-1.47 (-1.8 to -1.2)
SecondaryChange From Baseline in the Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score at Week 24

The AIMS dyskinesia total score was defined as the sum of the scores of AIMS items 1 through 7. The scores for each item ranged from 0 (no dyskinesia) to 4 (severe dyskinesia). If any of the seven items had a missing value, the total score for that participant/visit was set equal to missing. The AIMS dyskinesia total score can therefore range from 0 to 28, with higher scores indicating greater severity.

Time frame:
Baseline, Week 24
Reported as:
Mean · score on a scale
Change From Baseline in the Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score at Week 24
score on a scaleValbenazine
Change From Baseline in the Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score at Week 24-6.8 (-7.75 to -5.81)

Adverse events

Collected over Up to 26 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Valbenazine1/59 (1.7%)6/59 (10.2%)6/59 (10.2%)
Most frequent serious events
Most frequent serious events
EventValbenazine
Peptic ulcerGastrointestinal disorders1/59
Chest painGeneral disorders1/59
Medication errorInjury, poisoning and procedural complications1/59
Road traffic accidentInjury, poisoning and procedural complications1/59
Suicidal ideationPsychiatric disorders1/59
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/59
Most frequent other events
Most frequent other events
EventValbenazine
NauseaGastrointestinal disorders3/59
SomnolenceNervous system disorders3/59

Baseline characteristics

The Safety Analysis Set included all enrolled participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Valbenazine
Mean61.3 ± 11.99
Sex: Female, Male
Sex: Female, Male(Participants)Valbenazine
Female34
Male25
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Valbenazine
Hispanic or Latino24
Not Hispanic or Latino35
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Valbenazine
American Indian or Alaska Native0
Asian1
Black or African American17
White38
Native Hawaiian or Other Pacific Islander0
Other2
Multiple1
08

Study locations

18 sites
  • Neurocrine Clinical Site
    Bryant, Arkansas 72022, United States
  • Neurocrine Clinical Site
    Anaheim, California 92805, United States
  • Neurocrine Clinical Site
    Orange, California 92868, United States
  • Neurocrine Clinical Site
    Torrance, California 90504, United States
  • Neurocrine Clinical Site
    Bonita Springs, Florida 34134, United States
  • Neurocrine Clinical Site
    Miami, Florida 33176, United States
  • Neurocrine Clinical Site
    Miami Lakes, Florida 33016, United States
  • Neurocrine Clinical Site
    Okeechobee, Florida 34972, United States
  • Neurocrine Clinical Site
    Tampa, Florida 33629, United States
  • Neurocrine Clinical Site
    Atlanta, Georgia 30328, United States
  • Neurocrine Clinical Site
    Augusta, Georgia 30912, United States
  • Neurocrine Clinical Site
    Marietta, Georgia 30060, United States
  • Neurocrine Clinical Site
    Lincoln, Nebraska 68526, United States
  • Neurocrine Clinical Site
    Beechwood, Ohio 44122, United States
  • Neurocrine Clinical Site
    Oklahoma City, Oklahoma 73112, United States
  • Neurocrine Clinical Site
    DeSoto, Texas 75115, United States
  • Neurocrine Clinical Site
    El Paso, Texas 79902, United States
  • Neurocrine Clinical Site
    Houston, Texas 77030, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Dec 2024, 19 months.

Results were first posted in Jan 2026, 1 year after primary completion.

Of 88 phase 4 interventional studies under Schizophrenia, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 63. This study's 19 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2023
First posted
May 16, 2023
StartActual
May 9, 2023
Primary completionActual
Dec 27, 2024
CompletionActual
Dec 27, 2024
Results first posted
Jan 16, 2026
Last update
Jan 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05859698
Responsible party
Sponsor
First posted
May 16, 2023
Start date
May 9, 2023
Primary completion
Dec 27, 2024
Completion
Dec 27, 2024
Results posted
Jan 16, 2026
Last update
Jan 16, 2026

Study contacts

Clinical Development Lead
study director · Neurocrine Biosciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valbenazine

Start the discussion